Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia

Testing novel therapies for hematologic malignancies requires human cell models that reflect the combinatorial complexity of genetic mutations observed in patients. Ebert and colleagues use multiplex CRISPR/Cas9-based targeting of human hematopoietic stem and progenitor cells to model the genetics of clonal hematopoiesis and myeloid neoplasms in vivo.

http://ift.tt/2xWcjnw